Merus surges after Genmab says it will acquire it for $8 billion
Danish biotech Genmab announced on Monday that it will acquire cancer startup Merus in an all-cash deal worth about $8 billion.
Genmab is buying Merus for $97 per share, a roughly 40% premium over its closing price as of Friday. The deal was approved unanimously by both companies’ boards, Genmab said.
Merus’ experimental drug, petosemtamab, has shown encouraging results in mid-stage trials for metastatic head and neck cancer. The stock jumped more than 30% in premarket trading once the acquisition was announced.